The Coin Group develops genomic and transcriptomic tools to develop biomarkers for rapid characterization of disease state and prediction of drug susceptibility, with the aim of decreasing the time taken from hospital admission to administering the right treatment. We currently focus on infectious disease as well as cancer.
